Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

Delayed Quote. Delayed  - 02/20 04:24:00 pm
13830 ILa   +0.58%
02/19 TEVA PHARMACEUT : drug pipeline could contain blockbusters
02/16 TEVA PHARMACEUT : outgoing CEO earned NIS 20m in 2016
02/16 GENERIC COMPETI : Acor)
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Tel Aviv Stock Exchange
02/14/2017 02/15/2017 02/16/2017 02/19/2017 02/20/2017 Date
12710(c) 13500(c) 13390(c) 13750(c) 13910(c) Last
771 738 881 319 1 221 250 470 549 434 963 Volume
+1.60% +6.22% -0.81% +2.69% +1.16% Change
More quotes
Financials ($)
Sales 2017 23 456 M
EBIT 2017 7 071 M
Net income 2017 4 011 M
Debt 2017 25 854 M
Yield 2017 3,24%
Sales 2018 23 190 M
EBIT 2018 7 119 M
Net income 2018 4 202 M
Debt 2018 21 087 M
Yield 2018 3,29%
P/E ratio 2017 9,44
P/E ratio 2018 9,14
EV / Sales2017 2,71x
EV / Sales2018 2,53x
Capitalization 37 675 M
More Financials
Company
Teva Pharmaceutical Industries Ltd. engages in the provision of pharmaceutical services.It operates through the following two segments: Generic and Specialty Medicine.The Generic segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including... 
More about the company
Surperformance© ratings of Teva Pharmaceutical Indust
Trading Rating : Investor Rating :
More Ratings
Latest news on TEVA PHARMACEUTICAL INDUST
02/19 TEVA PHARMACEUTICAL INDUSTRIES : drug pipeline could contain blockbusters
02/16 TEVA PHARMACEUTICAL INDUSTRIES : outgoing CEO earned NIS 20m in 2016
02/16 TEVA PHARMACEUTICAL INDUSTRIES : Bernstein Liebhard LLP Investigates Claims On B..
02/16 GENERIC COMPETITORS A LOOMING THREAT : Acor)
02/16 TEVA PHARMACEUTICAL INDUSTRIES : Files 2016 Annual Report on Form 20-F
02/14 TEVA PHARMACEUTICAL INDUSTRIES LIMIT : Today's Research Reports on Stocks to Wat..
02/14DJTEVA PHARMACEUTICAL INDUSTRIES : Posts Loss on a Write-Down -- WSJ
02/13 Zeltiq, US Steel and Chemours rise; Hain Celestial plunges
02/13 TEVA PHARMACEUTICAL INDUSTRIES : Q4 results provide badly needed boost
02/13 TEVA PHARMACEUTICAL INDUSTRIES : TEVA) Gains with Earnings In Wings
More news
Sector news : Pharmaceuticals - NEC
08:25aDJASTRAZENECA : licenses Cancer Drug Zoladex to TerSera for the US, Canada
02/17DJSHIRE : Files 8K - Other Events
02/17 European shares retreat after week of gains; Allianz rallies after update
02/17 ASTRAZENECA : Top AstraZeneca shareholder Woodford adds to stake, bullish on out..
02/17DJROCHE : U.S. Obtains Records in Lobbyist Probe -- WSJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
02/16Teva Pharmaceutical Industries Limited $TEVA Stock Rating Lowered by Mizuho  
02/15Teva Pharmaceutical Industries Limited $TEVA Given a $43.00 Price Target at O.. 
02/15Teva Pharmaceutical Industries Limited's hold rating reiterated at Wells Farg.. 
02/14Top story today -- Celgene co-founder Sol Barer bags a Johns Hopkins immuno-o..
4
02/14Teva Pharmaceutical Industries Limited $TEVA Shares Sold by Loudon Investment.. 
More tweets
Qtime:40
News from SeekingAlpha
02/15 Teva-Takeda Japanese Joint Venture Adds $450M Revenue For Q4
02/15 Teva Pharmaceuticals Has Bottomed This Time
02/14 Teva Management's Brilliant Hidden Message
02/14 Is Teva Pharmaceuticals Worth Considering?
02/14 WALL STREET BREAKFAST : Yellen Has Date With Congress
Advertisement
Chart TEVA PHARMACEUTICAL INDUST
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Full-screen chart
Technical analysis trends TEVA PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 46,0 $
Spread / Average Target 24%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Yitzhak Peterburg President & Chief Executive Officer
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Eyal Desheh Chief Financial Officer & Group Executive VP
Michael R. Hayden President-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
TEVA PHARMACEUTICAL IN..-3.18%36 414
JOHNSON & JOHNSON3.17%323 362
ROCHE HOLDING LTD.4.69%210 814
PFIZER INC.3.51%204 018
NOVARTIS AG3.91%202 998
MERCK & CO., INC.11.08%180 289
More Results